<DOC>
	<DOC>NCT00636246</DOC>
	<brief_summary>This study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.</brief_summary>
	<brief_title>A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>Subjects must fulfill the criteria for MDD without psychotic features as defined by DSMIV, based on clinical assessment and confirmed by Structural Clinical Interview for DSMIV Axis I DisorderClinical Version (SCIDI) plus the MDD Specifiers included in the Research Version of SCIDI. HAMD (17item) ≥ 22 at Screening (Visit 1) and &gt; 20 at Baseline (Visit 2). Minimum CGIS ≥ 4 at Screening (Visit 1) and at Baseline (Visit 2). Known failure to satisfactory respond after adequate dose and duration (12 weeks) of treatment with clomipramine and one SSRI, or with two or more SSRIs. Subjects with &gt; 20% HAMD (17item) improvement (decrease) from Screening (Visit 1) at Baseline (Visit 2). Subjects with uncorrected hypothyroidism or hyperthyroidism.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>